For research use only. Not for therapeutic Use.
Abrezekimab（Cat No.:I042187）is an investigational monoclonal antibody that targets IL-17A, a pro-inflammatory cytokine involved in autoimmune diseases. IL-17A plays a critical role in promoting inflammation, especially in conditions like psoriasis, rheumatoid arthritis, and ankylosing spondylitis. By inhibiting IL-17A, abrezekimab aims to reduce inflammation and prevent tissue damage associated with these diseases. It is being studied in clinical trials for its potential to treat a range of autoimmune and inflammatory conditions, with the goal of improving symptom control, reducing flare-ups, and enhancing quality of life for patients with chronic inflammatory diseases.
| Catalog Number | I042187 |
| CAS Number | 2043952-59-4 |
| Purity | ≥95% |
